Fig. 5 From: Targeting the RNA m6A modification for cancer immunotherapyNanoparticles (NPs) encapsulating m6A modification molecules can specifically target TAMs. NPs that deliver Mettl3, Mettl14, or Sp red2 mRNA or Irakm siRNA specifically into TAMs can reprogram the macrophages from the M2-type to the M1-type. This switch reshapes the TME and inhibits tumor progression. Figure created with BioRender.comBack to article page